chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 0.22
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5, TTOX
Symptoms: Metabolic function test normal, Oxygen supplementation, Pallor, Vomiting, X-ray gastrointestinal tract normal
Clinical narrative: After vaccination on 6/5/08 during routine WCC the patient had inconsolable crying for approximately 24 hours.  On D#5 post vaccine after a second crying bout the mother tried to soothe the child with a warm bath.  The child appeared dusky shortly thereafter and within 10-15minutes became apneic, mottled, and gray.  9-1-1 was called and EMS arrived within 5 minutes.   The child recevied oxygen and stimulation. The patient vomited x2 in the ambulance. Within a few minutes of arrival the patient color returned and the patient perked up.  The patient was obsrved for 48 hours in the hospital with an unknown eitiology for the ALTE. 6/20/08-records received for DOS 6/10/08-overnight stay uneventful. History of several weeks C/O cough worse at night. DX:ALTE.
Age: 0.22
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5, TTOX
Symptoms: Crying, Livedo reticularis, Respiratory arrest, Skin discolouration
Clinical narrative: After vaccination on 6/5/08 during routine WCC the patient had inconsolable crying for approximately 24 hours.  On D#5 post vaccine after a second crying bout the mother tried to soothe the child with a warm bath.  The child appeared dusky shortly thereafter and within 10-15minutes became apneic, mottled, and gray.  9-1-1 was called and EMS arrived within 5 minutes.   The child recevied oxygen and stimulation. The patient vomited x2 in the ambulance. Within a few minutes of arrival the patient color returned and the patient perked up.  The patient was obsrved for 48 hours in the hospital with an unknown eitiology for the ALTE. 6/20/08-records received for DOS 6/10/08-overnight stay uneventful. History of several weeks C/O cough worse at night. DX:ALTE.
Age: 1.08
Sex: F
Vaccine: DTAP, MMR, PNC, VARCEL
Symptoms: Inappropriate schedule of drug administration
Clinical narrative: gave Dtap too soon
Age: 43.0
Sex: F
Vaccine: RAB
Symptoms: Dizziness, Feeling abnormal, Feeling cold, Headache, Hyperhidrosis
Clinical narrative: Yesterday I went for my 4th shot, the nurse had commented that the shot is "no longer pink" like the previous shots i had recived. I had the shot around 11:30am by 7pm I started getting cold, my skin was hot i was lethargic & dizzy, I didnt go to the ER as i was an emt for 4yrs & told my boyfriend to just watch my breathing & take me if anything changed. It was over 85 degrees outside and i was wrapped in blankets & still freezing finally at 2am the reverse occured & i was sweating I awoke this morning with a severe headache, muscle aches and a fuzzy feeling in my head. I called the ER to let them know what had happened & thier response was perhaps i was getting the flu. it is now 7pm and i started feeling better around 3pm. I just wanted to tell someone so that someone is aware. I am not getting the flu and am scared to have my last shot next week.
Age: 43.0
Sex: F
Vaccine: RAB
Symptoms: Lethargy, Myalgia, Skin warm
Clinical narrative: Yesterday I went for my 4th shot, the nurse had commented that the shot is "no longer pink" like the previous shots i had recived. I had the shot around 11:30am by 7pm I started getting cold, my skin was hot i was lethargic & dizzy, I didnt go to the ER as i was an emt for 4yrs & told my boyfriend to just watch my breathing & take me if anything changed. It was over 85 degrees outside and i was wrapped in blankets & still freezing finally at 2am the reverse occured & i was sweating I awoke this morning with a severe headache, muscle aches and a fuzzy feeling in my head. I called the ER to let them know what had happened & thier response was perhaps i was getting the flu. it is now 7pm and i started feeling better around 3pm. I just wanted to tell someone so that someone is aware. I am not getting the flu and am scared to have my last shot next week.
Age: 68.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site induration, Injection site mass, Injection site pruritus
Clinical narrative: Patient came in on 6/12/08 after receiving injection on 6/6/08 complaining of itching and a mass of hardness around the area of recieving Zostavax.  She indicated that it has improved each day.  I instructed her to see her physician and have it check out.  The physician didn't seem to think that any treatment was necessary.
Age: 15.0
Sex: F
Vaccine: UNK
Symptoms: Blood test normal, Chest X-ray abnormal, Chest discomfort, Diagnostic procedure, Dyspnoea
Clinical narrative: Gardasil shot was given to my daughter on June 5, 2008 at 3:00pm by 8:00 pm the same evening she informed me she could not breath. Her chest and throat felt tight. She was taken to the emergency room on June 6, 2008 at 2:00pm. She was given an EKG which came out normal, the dorctor there found no signs of sickness, (eg. cold, flu, asthma, or bronchitis) She was given a nebulizer treatment at about 4:00pm which didn't help her at all. She was sent home with a prescription of Albuterol which has not helped her. She contined to experience difficulty breathing through the weekend and was taken back to her Primary Physician on Monday June 9, 2008. Her Doctor gave her a breathing test which she said was abnormal, and listened to her breathing. Again, there was no sign of a cold,cough or flu or bronchitis. Her doctor gave her a perscription for Methylpred  which did not help her and ordered a blood panel and chest x-ray. The blood panel was determined to be normal, but her doctor claims based on the x-ray she would be diagnosed with Bronchitis. Which did not make sense to me since she had no signs of Bronchitis. She had no cough, fever or phlem. Her Dr prescribed Zithromax Z pak. When I went to get the prescription filled I asked the Pharmacist if it was possible to have Bronchitis without any  coughing, wheezing or phlem. The Pharmacist said NO. She advised me to get a second opinion. I took my daughter to an Alergist on Wed. June 11, 2008. Once he checked her he said that it is a possibility her condition was an adverse reaction to the Gardasil shot. He said the treatment he would prescribe would treat both an adverse reaction to the Gardasil shot and bronchitis. My mother who works for a Physicians office described to two physicians the situation my daughter was experiencing and both concluded that without any signs of cough, wheezing and phlem it was probably an adverse reaction to the Gardasil shot. It has been 7 days since my daughter took the shot and she is still have extreme difficulty breathing.
Age: 15.0
Sex: F
Vaccine: UNK
Symptoms: Electrocardiogram normal, Throat tightness
Clinical narrative: Gardasil shot was given to my daughter on June 5, 2008 at 3:00pm by 8:00 pm the same evening she informed me she could not breath. Her chest and throat felt tight. She was taken to the emergency room on June 6, 2008 at 2:00pm. She was given an EKG which came out normal, the dorctor there found no signs of sickness, (eg. cold, flu, asthma, or bronchitis) She was given a nebulizer treatment at about 4:00pm which didn't help her at all. She was sent home with a prescription of Albuterol which has not helped her. She contined to experience difficulty breathing through the weekend and was taken back to her Primary Physician on Monday June 9, 2008. Her Doctor gave her a breathing test which she said was abnormal, and listened to her breathing. Again, there was no sign of a cold,cough or flu or bronchitis. Her doctor gave her a perscription for Methylpred  which did not help her and ordered a blood panel and chest x-ray. The blood panel was determined to be normal, but her doctor claims based on the x-ray she would be diagnosed with Bronchitis. Which did not make sense to me since she had no signs of Bronchitis. She had no cough, fever or phlem. Her Dr prescribed Zithromax Z pak. When I went to get the prescription filled I asked the Pharmacist if it was possible to have Bronchitis without any  coughing, wheezing or phlem. The Pharmacist said NO. She advised me to get a second opinion. I took my daughter to an Alergist on Wed. June 11, 2008. Once he checked her he said that it is a possibility her condition was an adverse reaction to the Gardasil shot. He said the treatment he would prescribe would treat both an adverse reaction to the Gardasil shot and bronchitis. My mother who works for a Physicians office described to two physicians the situation my daughter was experiencing and both concluded that without any signs of cough, wheezing and phlem it was probably an adverse reaction to the Gardasil shot. It has been 7 days since my daughter took the shot and she is still have extreme difficulty breathing.
Age: 1.6
Sex: F
Vaccine: MMR, VARCEL
Symptoms: Blood test normal, Erythema, Pyrexia, Staring, Tremor
Clinical narrative: Patient was sitting in her car seat, and her hands started trembling. Her eyes were half open to closed. Her legs were 'fidgety'(trembling, but somewhat restricted maybe because of rear-facing seat). She had a vacant stare. She gradually started to look around more, stopped trembling but still was very vacant and not saying anything. We headed towards the hospital. She gradually came around, but still very quiet. Roughly 30 minutes later, she was back to herself. She had a slight fever (about 100F) and red spots on her back when examined at the hospital. She was kept overnight for observation, as they suspected a seizure. 6/13/08-History and Physical report for DOS 1/27/08 received-presented to ED after episode of staring off into space, not entriely responsive with twitching of left hand and arm. Did not respond to calling of name. Postictal period.PE: scattered lymphadenopathy neck area.  Temperature spike 100.4. Firsat time nonfebrile seizure.  6/20/08-records received for DOS 1/27-1/28/08-Seizure admitted for overnight observation, uneventful.
Age: 1.6
Sex: F
Vaccine: MMR, VARCEL
Symptoms: Urine analysis normal
Clinical narrative: Patient was sitting in her car seat, and her hands started trembling. Her eyes were half open to closed. Her legs were 'fidgety'(trembling, but somewhat restricted maybe because of rear-facing seat). She had a vacant stare. She gradually started to look around more, stopped trembling but still was very vacant and not saying anything. We headed towards the hospital. She gradually came around, but still very quiet. Roughly 30 minutes later, she was back to herself. She had a slight fever (about 100F) and red spots on her back when examined at the hospital. She was kept overnight for observation, as they suspected a seizure. 6/13/08-History and Physical report for DOS 1/27/08 received-presented to ED after episode of staring off into space, not entriely responsive with twitching of left hand and arm. Did not respond to calling of name. Postictal period.PE: scattered lymphadenopathy neck area.  Temperature spike 100.4. Firsat time nonfebrile seizure.  6/20/08-records received for DOS 1/27-1/28/08-Seizure admitted for overnight observation, uneventful.
Age: 33.0
Sex: M
Vaccine: TDAP
Symptoms: Chills, Influenza like illness, Injection site pain, Lethargy, Myalgia
Clinical narrative: flu-like symptoms began a few hours after the vaccination and lasted a day. Specifically, lethargy, low-grade fever, muscle soreness, and chills. Also, soreness at the injection site lasted four days.
Age: 33.0
Sex: M
Vaccine: TDAP
Symptoms: Pyrexia
Clinical narrative: flu-like symptoms began a few hours after the vaccination and lasted a day. Specifically, lethargy, low-grade fever, muscle soreness, and chills. Also, soreness at the injection site lasted four days.
Age: 56.0
Sex: F
Vaccine: TDAP
Symptoms: Injection site erythema, Injection site pruritus, Injection site warmth
Clinical narrative: Red area below injection site about 5 cm x 5 cm, warm to touch and itchy - patient to apply ice and use Benadryl prn.
Age: 11.0
Sex: M
Vaccine: MNQ
Symptoms: Vaccination complication
Clinical narrative: Seems to be resolving.  Apply cold compress 3x TID and may take TYLENOL if pain occurs.
Age: 0.2
Sex: F
Vaccine: DTAPHEPBIP, PNC, RV5
Symptoms: Injection site discolouration, Injection site erythema
Clinical narrative: Given PEDIARIX L thigh 6-9-08 afternoon, began w/ purple red that pm.  Seen 6/10 at clinic with 35mm x 18mm irreg red/purple non-blanching patch at injection site, no color, no pain. Afebrile.  F/U 6-12-08 - much better - 30 x 3mm..
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site rash
Clinical narrative: On 6/5/08 - reddish rash/bump appeared around site of injection.  Rash lasted for 1 week.  Rash starting to go down on 6/12/08.
Age: 17.0
Sex: M
Vaccine: MNQ, TDAP
Symptoms: Loss of consciousness
Clinical narrative: After patient received vaccines, the patient passed out on exam table and came to shortly. No O2 required. Patient recovered shortly after episode and went home.
Age: 5.0
Sex: F
Vaccine: DTAP, IPV, MMR, VARCEL
Symptoms: Cellulitis, Erythema, Skin warm, Tenderness
Clinical narrative: Warm, red and tender deltoid area; cellulitis.
Age: 1.0
Sex: M
Vaccine: MMR, VARCEL
Symptoms: Injection site mass, Rash
Clinical narrative: Pt develop a bump at site of injection.  Mild rash on face.  I was given 10ml BENADRYL oral.
Age: 2.0
Sex: M
Vaccine: DTAP, MMR, VARCEL
Symptoms: Erythema, Skin warm, Swelling
Clinical narrative: Swelling, redness, warm to touch.
Age: 61.0
Sex: F
Vaccine: PPV
Symptoms: Body temperature increased, Erythema, Skin warm, Swelling
Clinical narrative: On 06/9/08 patient received pneumonia vaccine on 6/11 2x2 reddened raised warm area present with temperature of 100. Patient prescribed Augmentin; to follow up on 6/13/08
Age: 18.0
Sex: M
Vaccine: MNQ
Symptoms: Biopsy lymph gland, Biopsy site unspecified normal, Laboratory test normal, Lymphadenopathy
Clinical narrative: Initial report received from a parent (who is also a PA) on 22 February 2008.  An 18 year old, male patient (with a history of intermittent lymphadenopathy) developed large lymph nodes during the summer of 2007, after he had received MENACTRA (lot number, route and site of administration not reported) in November 2006.  The symptoms have persisted until the time of the report.  The patient has undergone an extensive work-up with allergists and infectious disease specialist doctors.  The node biopsies and all other tests have been negative.  They've ruled out benign hyperplastic lymph node conditions.  The mother has been told he does have a predominant T cell response.  It was unknown if patient was on any medications or had any illness at the time of vaccination.
Age: 11.0
Sex: M
Vaccine: HEPA, MNQ, TDAP
Symptoms: Dyspnoea, Injection site erythema, Injection site pruritus, Injection site swelling, Respiratory disorder
Clinical narrative: Initial report received from a parent of a patient on 25 February 2008.  An 11 year old, male patient (with a history of asthma with no exacerbations a few years) developed itchiness, redness, and swelling the size of a quarter at the injection of the right deltoid, the day after receiving MENACTRA (lot number unknown) intra-muscularly in the right deltoid and Hep A vaccine (manufacturer not reported, lot number unknown) intramuscularly in the right deltoid on 19 February 2008.  The patient also received ADACEL (lot number unknown) intramuscularly in the left deltoid on the same day.  The reaction at the injection site progressed to the size of an orange.  The patient was seen by a physician and prescribed Claritin.  At the time of the report, the swelling had decreased but was still present.  After the vaccination, the patient began having mild respiratory symptoms - breathing more heavily and had a mild wheeze.  At the time of the vaccination, the patient was on Albuterol - PRN and did not have any illness.  It was reported the patient had not recovered.
Age: 11.0
Sex: M
Vaccine: HEPA, MNQ, TDAP
Symptoms: Wheezing
Clinical narrative: Initial report received from a parent of a patient on 25 February 2008.  An 11 year old, male patient (with a history of asthma with no exacerbations a few years) developed itchiness, redness, and swelling the size of a quarter at the injection of the right deltoid, the day after receiving MENACTRA (lot number unknown) intra-muscularly in the right deltoid and Hep A vaccine (manufacturer not reported, lot number unknown) intramuscularly in the right deltoid on 19 February 2008.  The patient also received ADACEL (lot number unknown) intramuscularly in the left deltoid on the same day.  The reaction at the injection site progressed to the size of an orange.  The patient was seen by a physician and prescribed Claritin.  At the time of the report, the swelling had decreased but was still present.  After the vaccination, the patient began having mild respiratory symptoms - breathing more heavily and had a mild wheeze.  At the time of the vaccination, the patient was on Albuterol - PRN and did not have any illness.  It was reported the patient had not recovered.
Age: 42.0
Sex: M
Vaccine: MNQ
Symptoms: Axillary pain, Lymphadenopathy, Oedema, Pain in extremity, Pyrexia
Clinical narrative: A 42-year-old male patient, with no illness at the time of vaccination, had received a first dose, right deltoid, intramuscular injection of MENACTRA, lot U2558AA, on 08 February 2008. Twelve hours post-vaccination, the patient developed a fever of 100.0 degrees Fahrenheit. Two days following vaccination, the patient noticed edema and tenderness of the right axilla. The patient was treated with MOTRIN. The event did not require medical examination. At the time of this report, the patient had recovered. Follow-up information received on 12 February 2008 from a health care professional. Per the reporter, there was no additional information concerning the tetanus vaccine that was administered ten years prior by the patient's family physician. Additional information was not provided.
Age: 13.0
Sex: F
Vaccine: HPV4, MNQ
Symptoms: Blood test normal, Full blood count normal, Musculoskeletal discomfort, Petechiae
Clinical narrative: Initial report received on 13 February 2008 from a health care professional. A 13-year-old female patient with no past medical history, and no known allergies, had received a first, intramuscular right deltoid dose of MENACTRA (lot number U2551AA); and a second, intramuscular "left" dose of GARDASIL (manufacturer Merck, lot number 0802U) on 05 February 2008. Approximately three days later, the patient complained of discomfort in her hips bilaterally; and had developed petechiae in the hip and buttock area bilaterally. No treatment was required. Reportedly, blood work was within normal limits. At the time of this report, the patient was slightly improving, but was not considered to be recovered. Follow-up information was received from the reporter on 18 March 2008. The Gardasil was given in the left deltoid. The patient's father was a physician, and ordered a CBC which was reported as "normal". Per the health professional, the form was "complete".
Age: 12.0
Sex: F
Vaccine: MNQ, TDAP, MNQ, TDAP
Symptoms: Guillain-Barre syndrome, Lumbar puncture
Clinical narrative: Initial report received on 10 April 2008 from the Center for Disease Control and Prevention VAERS # 303612.  The original reporter to the CDC was a nurse.  A 12-year-old female patient, who had no concurrent illnesses, and a medical history of asthma, allergy NOS, growth hormone deficiency, and tonsillectomy/adenoidectomy, had received a first, intramuscular left arm dose of MENACTRA (Lot # U2545AA); and a first, intramuscular, right arm dose of BOOSTRIX (manufacturer GlaxoSmithKline, Lot # AC52B024AA) on 02 January 2008 at 09:00.  Sixteen days later, the patient was hospitalized at 09:00 A.M. with symptoms that began approximately six days earlier of back, neck and leg pain; stiffness, nausea, intermittent abdominal pain, emesis, decreased appetite, decreased activity, fatigue, excess sleepiness, and five pound weight loss.  The patient was admitted to the intensive care unit and neurology and infectious disease consults was completed.  At some time after admission to the hospital, the patient developed left facial paralysis.  Relevant diagnostic testing included an MRI of the brain and spine that were normal, lumbar puncture that revealed cerebral spinal fluid with white blood cell count 8 (H), protein 335 (H), and glucose 60 (N).  Blood, urine and cerebral spinal fluid culture and sensitivity were negative.  An echocardiogram was within normal limits.  A Complete Blood Cell Count showed white blood cells 18.9 (H), segs 88% (H), and lymphs 9% (L).  An Erythrocyte Sedimentation Rate (ESR) was 40 (H).  A chemistry panel was essentially within normal limits with total protein 8.7 (H).  A C-reactive protein revealed quant 0.501 (H).  A urinalysis was abnormal with 2+ ketones.  Mononucleosis Spot test and flu A&B were negative.  A chest x-ray was within normal limits.  An ultrasound of the "LUE" was within normal limits.  The patient was diagnosed with Guillain-Barre syndrome and received corrective treatment with intravenous Immunoglobulin's for five days.  She improved dramatically with the intravenous Immunoglobulin's and physical therapy, and had resolution of the facial paralysis.  The patient was discharged to home on 26 January 2008, i.e., nine days after admission with outpatient physical therapy and neurology follow-up.  The event was considered to be life threatening.  At the time of this report, it was "unknown" if the patient fully recovered.  It was reported that evaluation by an agency has determined that this case met the criteria for Guillain-Barre syndrome (GBS) using the case definition developed by the GBS working group.
Age: 12.0
Sex: F
Vaccine: MNQ, TDAP, MNQ, TDAP
Symptoms: Abdominal pain, Back pain, Blood culture negative, Blood product transfusion, C-reactive protein increased
Clinical narrative: Initial report received on 10 April 2008 from the Center for Disease Control and Prevention VAERS # 303612.  The original reporter to the CDC was a nurse.  A 12-year-old female patient, who had no concurrent illnesses, and a medical history of asthma, allergy NOS, growth hormone deficiency, and tonsillectomy/adenoidectomy, had received a first, intramuscular left arm dose of MENACTRA (Lot # U2545AA); and a first, intramuscular, right arm dose of BOOSTRIX (manufacturer GlaxoSmithKline, Lot # AC52B024AA) on 02 January 2008 at 09:00.  Sixteen days later, the patient was hospitalized at 09:00 A.M. with symptoms that began approximately six days earlier of back, neck and leg pain; stiffness, nausea, intermittent abdominal pain, emesis, decreased appetite, decreased activity, fatigue, excess sleepiness, and five pound weight loss.  The patient was admitted to the intensive care unit and neurology and infectious disease consults was completed.  At some time after admission to the hospital, the patient developed left facial paralysis.  Relevant diagnostic testing included an MRI of the brain and spine that were normal, lumbar puncture that revealed cerebral spinal fluid with white blood cell count 8 (H), protein 335 (H), and glucose 60 (N).  Blood, urine and cerebral spinal fluid culture and sensitivity were negative.  An echocardiogram was within normal limits.  A Complete Blood Cell Count showed white blood cells 18.9 (H), segs 88% (H), and lymphs 9% (L).  An Erythrocyte Sedimentation Rate (ESR) was 40 (H).  A chemistry panel was essentially within normal limits with total protein 8.7 (H).  A C-reactive protein revealed quant 0.501 (H).  A urinalysis was abnormal with 2+ ketones.  Mononucleosis Spot test and flu A&B were negative.  A chest x-ray was within normal limits.  An ultrasound of the "LUE" was within normal limits.  The patient was diagnosed with Guillain-Barre syndrome and received corrective treatment with intravenous Immunoglobulin's for five days.  She improved dramatically with the intravenous Immunoglobulin's and physical therapy, and had resolution of the facial paralysis.  The patient was discharged to home on 26 January 2008, i.e., nine days after admission with outpatient physical therapy and neurology follow-up.  The event was considered to be life threatening.  At the time of this report, it was "unknown" if the patient fully recovered.  It was reported that evaluation by an agency has determined that this case met the criteria for Guillain-Barre syndrome (GBS) using the case definition developed by the GBS working group.
Age: 12.0
Sex: F
Vaccine: MNQ, TDAP, MNQ, TDAP
Symptoms: CSF culture negative, CSF glucose normal, CSF protein increased, CSF white blood cell count increased, Chest X-ray normal
Clinical narrative: Initial report received on 10 April 2008 from the Center for Disease Control and Prevention VAERS # 303612.  The original reporter to the CDC was a nurse.  A 12-year-old female patient, who had no concurrent illnesses, and a medical history of asthma, allergy NOS, growth hormone deficiency, and tonsillectomy/adenoidectomy, had received a first, intramuscular left arm dose of MENACTRA (Lot # U2545AA); and a first, intramuscular, right arm dose of BOOSTRIX (manufacturer GlaxoSmithKline, Lot # AC52B024AA) on 02 January 2008 at 09:00.  Sixteen days later, the patient was hospitalized at 09:00 A.M. with symptoms that began approximately six days earlier of back, neck and leg pain; stiffness, nausea, intermittent abdominal pain, emesis, decreased appetite, decreased activity, fatigue, excess sleepiness, and five pound weight loss.  The patient was admitted to the intensive care unit and neurology and infectious disease consults was completed.  At some time after admission to the hospital, the patient developed left facial paralysis.  Relevant diagnostic testing included an MRI of the brain and spine that were normal, lumbar puncture that revealed cerebral spinal fluid with white blood cell count 8 (H), protein 335 (H), and glucose 60 (N).  Blood, urine and cerebral spinal fluid culture and sensitivity were negative.  An echocardiogram was within normal limits.  A Complete Blood Cell Count showed white blood cells 18.9 (H), segs 88% (H), and lymphs 9% (L).  An Erythrocyte Sedimentation Rate (ESR) was 40 (H).  A chemistry panel was essentially within normal limits with total protein 8.7 (H).  A C-reactive protein revealed quant 0.501 (H).  A urinalysis was abnormal with 2+ ketones.  Mononucleosis Spot test and flu A&B were negative.  A chest x-ray was within normal limits.  An ultrasound of the "LUE" was within normal limits.  The patient was diagnosed with Guillain-Barre syndrome and received corrective treatment with intravenous Immunoglobulin's for five days.  She improved dramatically with the intravenous Immunoglobulin's and physical therapy, and had resolution of the facial paralysis.  The patient was discharged to home on 26 January 2008, i.e., nine days after admission with outpatient physical therapy and neurology follow-up.  The event was considered to be life threatening.  At the time of this report, it was "unknown" if the patient fully recovered.  It was reported that evaluation by an agency has determined that this case met the criteria for Guillain-Barre syndrome (GBS) using the case definition developed by the GBS working group.
Age: 12.0
Sex: F
Vaccine: MNQ, TDAP, MNQ, TDAP
Symptoms: Culture urine negative, Decreased activity, Decreased appetite, Echocardiogram normal, Facial palsy
Clinical narrative: Initial report received on 10 April 2008 from the Center for Disease Control and Prevention VAERS # 303612.  The original reporter to the CDC was a nurse.  A 12-year-old female patient, who had no concurrent illnesses, and a medical history of asthma, allergy NOS, growth hormone deficiency, and tonsillectomy/adenoidectomy, had received a first, intramuscular left arm dose of MENACTRA (Lot # U2545AA); and a first, intramuscular, right arm dose of BOOSTRIX (manufacturer GlaxoSmithKline, Lot # AC52B024AA) on 02 January 2008 at 09:00.  Sixteen days later, the patient was hospitalized at 09:00 A.M. with symptoms that began approximately six days earlier of back, neck and leg pain; stiffness, nausea, intermittent abdominal pain, emesis, decreased appetite, decreased activity, fatigue, excess sleepiness, and five pound weight loss.  The patient was admitted to the intensive care unit and neurology and infectious disease consults was completed.  At some time after admission to the hospital, the patient developed left facial paralysis.  Relevant diagnostic testing included an MRI of the brain and spine that were normal, lumbar puncture that revealed cerebral spinal fluid with white blood cell count 8 (H), protein 335 (H), and glucose 60 (N).  Blood, urine and cerebral spinal fluid culture and sensitivity were negative.  An echocardiogram was within normal limits.  A Complete Blood Cell Count showed white blood cells 18.9 (H), segs 88% (H), and lymphs 9% (L).  An Erythrocyte Sedimentation Rate (ESR) was 40 (H).  A chemistry panel was essentially within normal limits with total protein 8.7 (H).  A C-reactive protein revealed quant 0.501 (H).  A urinalysis was abnormal with 2+ ketones.  Mononucleosis Spot test and flu A&B were negative.  A chest x-ray was within normal limits.  An ultrasound of the "LUE" was within normal limits.  The patient was diagnosed with Guillain-Barre syndrome and received corrective treatment with intravenous Immunoglobulin's for five days.  She improved dramatically with the intravenous Immunoglobulin's and physical therapy, and had resolution of the facial paralysis.  The patient was discharged to home on 26 January 2008, i.e., nine days after admission with outpatient physical therapy and neurology follow-up.  The event was considered to be life threatening.  At the time of this report, it was "unknown" if the patient fully recovered.  It was reported that evaluation by an agency has determined that this case met the criteria for Guillain-Barre syndrome (GBS) using the case definition developed by the GBS working group.
Age: 12.0
Sex: F
Vaccine: MNQ, TDAP, MNQ, TDAP
Symptoms: Fatigue, Full blood count, Guillain-Barre syndrome, Influenza serology negative, Laboratory test normal
Clinical narrative: Initial report received on 10 April 2008 from the Center for Disease Control and Prevention VAERS # 303612.  The original reporter to the CDC was a nurse.  A 12-year-old female patient, who had no concurrent illnesses, and a medical history of asthma, allergy NOS, growth hormone deficiency, and tonsillectomy/adenoidectomy, had received a first, intramuscular left arm dose of MENACTRA (Lot # U2545AA); and a first, intramuscular, right arm dose of BOOSTRIX (manufacturer GlaxoSmithKline, Lot # AC52B024AA) on 02 January 2008 at 09:00.  Sixteen days later, the patient was hospitalized at 09:00 A.M. with symptoms that began approximately six days earlier of back, neck and leg pain; stiffness, nausea, intermittent abdominal pain, emesis, decreased appetite, decreased activity, fatigue, excess sleepiness, and five pound weight loss.  The patient was admitted to the intensive care unit and neurology and infectious disease consults was completed.  At some time after admission to the hospital, the patient developed left facial paralysis.  Relevant diagnostic testing included an MRI of the brain and spine that were normal, lumbar puncture that revealed cerebral spinal fluid with white blood cell count 8 (H), protein 335 (H), and glucose 60 (N).  Blood, urine and cerebral spinal fluid culture and sensitivity were negative.  An echocardiogram was within normal limits.  A Complete Blood Cell Count showed white blood cells 18.9 (H), segs 88% (H), and lymphs 9% (L).  An Erythrocyte Sedimentation Rate (ESR) was 40 (H).  A chemistry panel was essentially within normal limits with total protein 8.7 (H).  A C-reactive protein revealed quant 0.501 (H).  A urinalysis was abnormal with 2+ ketones.  Mononucleosis Spot test and flu A&B were negative.  A chest x-ray was within normal limits.  An ultrasound of the "LUE" was within normal limits.  The patient was diagnosed with Guillain-Barre syndrome and received corrective treatment with intravenous Immunoglobulin's for five days.  She improved dramatically with the intravenous Immunoglobulin's and physical therapy, and had resolution of the facial paralysis.  The patient was discharged to home on 26 January 2008, i.e., nine days after admission with outpatient physical therapy and neurology follow-up.  The event was considered to be life threatening.  At the time of this report, it was "unknown" if the patient fully recovered.  It was reported that evaluation by an agency has determined that this case met the criteria for Guillain-Barre syndrome (GBS) using the case definition developed by the GBS working group.
Age: 12.0
Sex: F
Vaccine: MNQ, TDAP, MNQ, TDAP
Symptoms: Lumbar puncture, Lymphocyte percentage decreased, Mononucleosis heterophile test negative, Musculoskeletal stiffness, Nausea
Clinical narrative: Initial report received on 10 April 2008 from the Center for Disease Control and Prevention VAERS # 303612.  The original reporter to the CDC was a nurse.  A 12-year-old female patient, who had no concurrent illnesses, and a medical history of asthma, allergy NOS, growth hormone deficiency, and tonsillectomy/adenoidectomy, had received a first, intramuscular left arm dose of MENACTRA (Lot # U2545AA); and a first, intramuscular, right arm dose of BOOSTRIX (manufacturer GlaxoSmithKline, Lot # AC52B024AA) on 02 January 2008 at 09:00.  Sixteen days later, the patient was hospitalized at 09:00 A.M. with symptoms that began approximately six days earlier of back, neck and leg pain; stiffness, nausea, intermittent abdominal pain, emesis, decreased appetite, decreased activity, fatigue, excess sleepiness, and five pound weight loss.  The patient was admitted to the intensive care unit and neurology and infectious disease consults was completed.  At some time after admission to the hospital, the patient developed left facial paralysis.  Relevant diagnostic testing included an MRI of the brain and spine that were normal, lumbar puncture that revealed cerebral spinal fluid with white blood cell count 8 (H), protein 335 (H), and glucose 60 (N).  Blood, urine and cerebral spinal fluid culture and sensitivity were negative.  An echocardiogram was within normal limits.  A Complete Blood Cell Count showed white blood cells 18.9 (H), segs 88% (H), and lymphs 9% (L).  An Erythrocyte Sedimentation Rate (ESR) was 40 (H).  A chemistry panel was essentially within normal limits with total protein 8.7 (H).  A C-reactive protein revealed quant 0.501 (H).  A urinalysis was abnormal with 2+ ketones.  Mononucleosis Spot test and flu A&B were negative.  A chest x-ray was within normal limits.  An ultrasound of the "LUE" was within normal limits.  The patient was diagnosed with Guillain-Barre syndrome and received corrective treatment with intravenous Immunoglobulin's for five days.  She improved dramatically with the intravenous Immunoglobulin's and physical therapy, and had resolution of the facial paralysis.  The patient was discharged to home on 26 January 2008, i.e., nine days after admission with outpatient physical therapy and neurology follow-up.  The event was considered to be life threatening.  At the time of this report, it was "unknown" if the patient fully recovered.  It was reported that evaluation by an agency has determined that this case met the criteria for Guillain-Barre syndrome (GBS) using the case definition developed by the GBS working group.
Age: 12.0
Sex: F
Vaccine: MNQ, TDAP, MNQ, TDAP
Symptoms: Neck pain, Neutrophil percentage increased, Nuclear magnetic resonance imaging brain normal, Nuclear magnetic resonance imaging normal, Pain in extremity
Clinical narrative: Initial report received on 10 April 2008 from the Center for Disease Control and Prevention VAERS # 303612.  The original reporter to the CDC was a nurse.  A 12-year-old female patient, who had no concurrent illnesses, and a medical history of asthma, allergy NOS, growth hormone deficiency, and tonsillectomy/adenoidectomy, had received a first, intramuscular left arm dose of MENACTRA (Lot # U2545AA); and a first, intramuscular, right arm dose of BOOSTRIX (manufacturer GlaxoSmithKline, Lot # AC52B024AA) on 02 January 2008 at 09:00.  Sixteen days later, the patient was hospitalized at 09:00 A.M. with symptoms that began approximately six days earlier of back, neck and leg pain; stiffness, nausea, intermittent abdominal pain, emesis, decreased appetite, decreased activity, fatigue, excess sleepiness, and five pound weight loss.  The patient was admitted to the intensive care unit and neurology and infectious disease consults was completed.  At some time after admission to the hospital, the patient developed left facial paralysis.  Relevant diagnostic testing included an MRI of the brain and spine that were normal, lumbar puncture that revealed cerebral spinal fluid with white blood cell count 8 (H), protein 335 (H), and glucose 60 (N).  Blood, urine and cerebral spinal fluid culture and sensitivity were negative.  An echocardiogram was within normal limits.  A Complete Blood Cell Count showed white blood cells 18.9 (H), segs 88% (H), and lymphs 9% (L).  An Erythrocyte Sedimentation Rate (ESR) was 40 (H).  A chemistry panel was essentially within normal limits with total protein 8.7 (H).  A C-reactive protein revealed quant 0.501 (H).  A urinalysis was abnormal with 2+ ketones.  Mononucleosis Spot test and flu A&B were negative.  A chest x-ray was within normal limits.  An ultrasound of the "LUE" was within normal limits.  The patient was diagnosed with Guillain-Barre syndrome and received corrective treatment with intravenous Immunoglobulin's for five days.  She improved dramatically with the intravenous Immunoglobulin's and physical therapy, and had resolution of the facial paralysis.  The patient was discharged to home on 26 January 2008, i.e., nine days after admission with outpatient physical therapy and neurology follow-up.  The event was considered to be life threatening.  At the time of this report, it was "unknown" if the patient fully recovered.  It was reported that evaluation by an agency has determined that this case met the criteria for Guillain-Barre syndrome (GBS) using the case definition developed by the GBS working group.
Age: 12.0
Sex: F
Vaccine: MNQ, TDAP, MNQ, TDAP
Symptoms: Protein total increased, Red blood cell sedimentation rate increased, Somnolence, Ultrasound scan normal, Urine analysis abnormal
Clinical narrative: Initial report received on 10 April 2008 from the Center for Disease Control and Prevention VAERS # 303612.  The original reporter to the CDC was a nurse.  A 12-year-old female patient, who had no concurrent illnesses, and a medical history of asthma, allergy NOS, growth hormone deficiency, and tonsillectomy/adenoidectomy, had received a first, intramuscular left arm dose of MENACTRA (Lot # U2545AA); and a first, intramuscular, right arm dose of BOOSTRIX (manufacturer GlaxoSmithKline, Lot # AC52B024AA) on 02 January 2008 at 09:00.  Sixteen days later, the patient was hospitalized at 09:00 A.M. with symptoms that began approximately six days earlier of back, neck and leg pain; stiffness, nausea, intermittent abdominal pain, emesis, decreased appetite, decreased activity, fatigue, excess sleepiness, and five pound weight loss.  The patient was admitted to the intensive care unit and neurology and infectious disease consults was completed.  At some time after admission to the hospital, the patient developed left facial paralysis.  Relevant diagnostic testing included an MRI of the brain and spine that were normal, lumbar puncture that revealed cerebral spinal fluid with white blood cell count 8 (H), protein 335 (H), and glucose 60 (N).  Blood, urine and cerebral spinal fluid culture and sensitivity were negative.  An echocardiogram was within normal limits.  A Complete Blood Cell Count showed white blood cells 18.9 (H), segs 88% (H), and lymphs 9% (L).  An Erythrocyte Sedimentation Rate (ESR) was 40 (H).  A chemistry panel was essentially within normal limits with total protein 8.7 (H).  A C-reactive protein revealed quant 0.501 (H).  A urinalysis was abnormal with 2+ ketones.  Mononucleosis Spot test and flu A&B were negative.  A chest x-ray was within normal limits.  An ultrasound of the "LUE" was within normal limits.  The patient was diagnosed with Guillain-Barre syndrome and received corrective treatment with intravenous Immunoglobulin's for five days.  She improved dramatically with the intravenous Immunoglobulin's and physical therapy, and had resolution of the facial paralysis.  The patient was discharged to home on 26 January 2008, i.e., nine days after admission with outpatient physical therapy and neurology follow-up.  The event was considered to be life threatening.  At the time of this report, it was "unknown" if the patient fully recovered.  It was reported that evaluation by an agency has determined that this case met the criteria for Guillain-Barre syndrome (GBS) using the case definition developed by the GBS working group.
Age: 12.0
Sex: F
Vaccine: MNQ, TDAP, MNQ, TDAP
Symptoms: Urine ketone body present, Vomiting, Weight decreased, White blood cell count increased
Clinical narrative: Initial report received on 10 April 2008 from the Center for Disease Control and Prevention VAERS # 303612.  The original reporter to the CDC was a nurse.  A 12-year-old female patient, who had no concurrent illnesses, and a medical history of asthma, allergy NOS, growth hormone deficiency, and tonsillectomy/adenoidectomy, had received a first, intramuscular left arm dose of MENACTRA (Lot # U2545AA); and a first, intramuscular, right arm dose of BOOSTRIX (manufacturer GlaxoSmithKline, Lot # AC52B024AA) on 02 January 2008 at 09:00.  Sixteen days later, the patient was hospitalized at 09:00 A.M. with symptoms that began approximately six days earlier of back, neck and leg pain; stiffness, nausea, intermittent abdominal pain, emesis, decreased appetite, decreased activity, fatigue, excess sleepiness, and five pound weight loss.  The patient was admitted to the intensive care unit and neurology and infectious disease consults was completed.  At some time after admission to the hospital, the patient developed left facial paralysis.  Relevant diagnostic testing included an MRI of the brain and spine that were normal, lumbar puncture that revealed cerebral spinal fluid with white blood cell count 8 (H), protein 335 (H), and glucose 60 (N).  Blood, urine and cerebral spinal fluid culture and sensitivity were negative.  An echocardiogram was within normal limits.  A Complete Blood Cell Count showed white blood cells 18.9 (H), segs 88% (H), and lymphs 9% (L).  An Erythrocyte Sedimentation Rate (ESR) was 40 (H).  A chemistry panel was essentially within normal limits with total protein 8.7 (H).  A C-reactive protein revealed quant 0.501 (H).  A urinalysis was abnormal with 2+ ketones.  Mononucleosis Spot test and flu A&B were negative.  A chest x-ray was within normal limits.  An ultrasound of the "LUE" was within normal limits.  The patient was diagnosed with Guillain-Barre syndrome and received corrective treatment with intravenous Immunoglobulin's for five days.  She improved dramatically with the intravenous Immunoglobulin's and physical therapy, and had resolution of the facial paralysis.  The patient was discharged to home on 26 January 2008, i.e., nine days after admission with outpatient physical therapy and neurology follow-up.  The event was considered to be life threatening.  At the time of this report, it was "unknown" if the patient fully recovered.  It was reported that evaluation by an agency has determined that this case met the criteria for Guillain-Barre syndrome (GBS) using the case definition developed by the GBS working group.
Age: 0.5
Sex: U
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, RV5
Symptoms: Intussusception
Clinical narrative: Information has been received from a physician concerning a 6 month old patient who on 30-MAY-2008 was vaccinated PO with the third 2.0 ml dose of ROTATEQ. Concomitant vaccinations included "normal 6 months scheduled vaccines." On 01-JUN-2008 2 days after vaccine was received, the patient experienced intussusception. The patient was hospitalized and had surgery on 03-JUN-2008. There was no product quality complaint. No additional information available. Intussusception was considered to be an other important medical event by the physician. Additional information has been requested.
Age: 0.5
Sex: U
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, RV5
Symptoms: Intussusception, Surgery
Clinical narrative: Information has been received from a physician concerning a 6 month old patient who on 30-MAY-2008 was vaccinated PO with the third 2.0 ml dose of ROTATEQ. Concomitant vaccinations included "normal 6 months scheduled vaccines." On 01-JUN-2008 2 days after vaccine was received, the patient experienced intussusception. The patient was hospitalized and had surgery on 03-JUN-2008. There was no product quality complaint. No additional information available. Intussusception was considered to be an other important medical event by the physician. Additional information has been requested.
Age: 69.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster, Pain
Clinical narrative: Information has been received from a physician concerning a 71 year old female with hypertension, hypothyroidism and no drug allergies who on 09-JAN-2007 was vaccinated with a dose of ZOSTAVAX (Oka/Merck). Concomitant drug therapy included unspecified thyroid replacement therapy and unspecified medication for hypertension. On 22-MAY-2008 the patient was diagnosed with shingles. The patient sought medical attention through a physician office visit. No labs or diagnostic studies were performed. The patient was treated with ZOVIRAX, prednisone and an unspecified pain medication. The patient was noted to be recovering at the time of this report. There was no product quality complaint. No other information was available at this time. Shingles was also considered to be disabling (related to pain) by the physician. Additional information has been requested.
Sex: F
Vaccine: MMR
Symptoms: Autism, Autism spectrum disorder
Clinical narrative: Information has been received from a nurse concerning a "less than 10 year old" female patient who on an unspecified date was vaccinated with MMR (Oka/Merck). Subsequently, the patient developed autism and was diagnosed with PDD. Unspecified medical attention was sought. It was unspecified if lab studies were performed. At the time of the report the patient's status was unknown. There was no product quality complaint involved. Upon internal review autism was considered an other important medical event. No further information was provided.
Age: 5.0
Sex: U
Vaccine: MMR
Symptoms: Autism
Clinical narrative: Information has been received from a licensed practical nurse concerning an approximately 5 year old patient who in approximately 2004 was vaccinated with a first dose of MMR II.  It was reported that the patient's mother thinks her child developed autism from the vaccine.  It was noted that the child received the vaccination when she was "around one years old."  Medical attention was sought, the office was contacted.  It was unspecified if lab studies were performed.  At the time of the report, the patient had not recovered.  There was no product quality complaint involved.  Upon internal review autism was considered an other important medical event.  No further information is available.
Age: 75.0
Sex: F
Vaccine: VARZOS
Symptoms: Blister, Erythema, Rash vesicular, Skin lesion
Clinical narrative: Shingles vaccine 5/15/08; Erythematous vesicles started 6/2-6/3/08; 6/3/08 - Increasing lesions - Admission to hospital "varicella like rash" 6/20/08-records received for DOS 6/3-6/6/08-DC DX:Disseminated herpes zoster. Treated with acyclovir. C/O progressive deveoping generalized rash. Chills
Age: 1.3
Sex: F
Vaccine: HEPA
Symptoms: Rash, Rash generalised, Wheezing
Clinical narrative: Mom reports patient developed rash over body and then face swelled and she developed wheezing.  911 was called to her home and child taken to ER where she was given BENADRYL and oxygen and observed for several hours and then discharged.  All rash and breathing difficulties resolved.  Noticed spots at 1PM & ambulance arrived 9:15PM. 6/30/08-records received for DOS 5/22/08-Impression: rash/allergic reaction. Presented to ED with 3-4 day pattern of decreased eating and urine output. Today woke up with rash, nonelevated on trunk, and soles of feet and palms and periorbital swelling.